Avectas

Description

Avectas develops the SoluScale cell engineering platform, combining a single-use SoluScale Cell Chamber and a compact automated manufacturing unit to support activation, transduction, expansion, and harvest of human primary T cells for cell therapy manufacturing.

Avectas is located in the Dublin ecosystem.

Related

• SarcuraSarcura develops a miniaturized, autonomous device platform for cell therapy manufacturing, using control intelligence, semiconductor chip…
• TQ TherapeuticsTQ Therapeutics operates a CELLfinity platform that delivers in vivo cell and gene therapies using a proprietary EXiVO automated approach…
• bit.biobit.bio provides deterministically programmed human iPSC-derived cells and CRISPR screening services for research and drug discovery,…
• SyngensysSyngensys develops synthetic gene promoters using transcriptional landscape analysis, computational design, selection, and validation to…
• IRUBISIRUBIS provides Monipa, a plug-and-play inline monitoring tool for downstream mAb and DNA/RNA bioprocesses that uses a mid-infrared…
• AAsgard TherapeuticsAsgard Therapeutics develops AT-108, an off-the-shelf gene therapy using direct cell reprogramming to activate professional…
• CiMaasCiMaas develops immunotherapy products that expand and engineer natural killer (NK) cells for adoptive cell therapy and CAR‑NK applications…
• Aenitis TechnologiesAenitis Technologies develops acoustic levitation devices and consumables for contact-free cell handling, providing modular GMP-ready…
• VRG TherapeuticsVRG Therapeutics designs therapeutic miniproteins using a proprietary platform that combines AI-driven protein engineering with wet-lab…